Comment le bénéfice par action récent de ACIU se compare-t-il aux attentes ?
Comment les revenus de AC Immune SA ACIU se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour AC Immune SA ?
Quel est le score de qualité des bénéfices pour AC Immune SA ?
Quand AC Immune SA publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de AC Immune SA ?
AC Immune SA a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$3.51
Prix d'ouverture
$3.53
Plage de la journée
$3.28 - $3.59
Plage de 52 semaines
$1.43 - $4
Volume
484.5K
Volume moyen
713.5K
BPA (TTM)
-0.72
Rendement en dividend
--
Capitalisation boursière
$333.3M
Qu’est-ce que ACIU ?
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.